title: Cinacalcet as adjunctive therapy for hereditary 1,25-dihydroxyvitamin D-resistant rickets.
abstract: Secondary hyperparathyroidism from inadequate calcium absorption in the gut, is the underlying pathophysiology for rachitic changes in hereditary vitamin D-resistant rickets (HVDRR). We describe a novel use of Cinacalcet to treat a child with HVDRR in whom conventional modes of therapy had to be discontinued. Cinacalcet therapy with high-dose oral calcium effectively normalized the metabolic abnormalities and bone condition. The relative ease of administration of the calcimimetic as a once- or twice-daily oral preparation, compared with traditional intravenous calcium administration, should encourage its move to the frontline of treatment of the disorder.
authors.affiliation: Section of Nephrology, Bone and Mineral Disorder Clinic, Children's Mercy Hospitals and Clinics, University of Missouri at Kansas City, Kansas City, MO 64108, USA.
authors.forename: Tarak
authors.initials: T
authors.lastname: Srivastava
authors.forename: Uri S
authors.initials: US
authors.lastname: Alon
mesh_terms: D000069449:Cinacalcet; D053098:Familial Hypophosphatemic Rickets / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D009281:Naphthalenes / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D009281:Naphthalenes; D000069449:Cinacalcet